Skip to content
StockMarketAgent

LLY vs NVO: side-by-side analysis

Cross-read of LLY (Eli Lilly and Company) versus NVO (NVO): LLY looks meaningfully undervalued at $975 versus a fair-value midpoint of $1466, while NVO appears in our peer table. Our current rating for LLY is Strong Buy.

Where LLY and NVO sit on fair value

LLY's composite fair-value range is $1025–$1936 (midpoint $1466), versus a current price of $975. NVO is one of LLY's closest sector neighbours and shows up directly in the peer table inside our full report. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.

Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between LLY and NVO is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.

Where they actually differ

LLY is classified as a hyper-growth stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. NVO, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 22.2× forward P/E with a PEG of 1.59 is not the same on LLY as it is on NVO unless they share the same growth profile, capital intensity, and moat half-life.

LLY's moat assessment is 9/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against NVO should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.

Which one wins on each dimension

Valuation: LLY looks meaningfully undervalued versus our fair-value midpoint. The full report's peer table compares LLY and NVO directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for LLY is bound by the kill-scenarios list in Section 2; the equivalent for NVO would need its own report. We do not co-rate two companies on a single page.

Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether LLY or NVO is the better expression of the same theme.

Bottom line — LLY or NVO?

Our rating for LLY is Strong Buy with a 88/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes NVO. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.

For the full evidence on LLY, including the explicit peer multiples versus NVO and the rest of the comp set, see the canonical report at /stocks/lly/analysis. For NVO's standalone report, see /stocks/nvo/analysis.

Frequently asked questions

LLY vs NVO: which is cheaper today?

LLY looks meaningfully undervalued at $975 versus a fair-value midpoint of $1466 (range $1025–$1936). The peer table inside the full report compares LLY and NVO directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.

Is LLY a better buy than NVO?

Our current rating for LLY is Strong Buy; we do not co-rate NVO on this page — see NVO's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.

What archetype is LLY?

Eli Lilly and Company is classified as a hyper-growth stock, which determines our deceleration curve, terminal multiple, and probability weights. NVO's own archetype is in its own report.

What is LLY's moat score versus NVO?

LLY's moat score is 9/10. The full moat section covers source, durability, and threat timeline; NVO's moat assessment is in its own standalone report.

Research for educational purposes. Not personalised investment advice. See the full LLY report for the canonical evidence.